MX394475B - Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes. - Google Patents

Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes.

Info

Publication number
MX394475B
MX394475B MX2019004402A MX2019004402A MX394475B MX 394475 B MX394475 B MX 394475B MX 2019004402 A MX2019004402 A MX 2019004402A MX 2019004402 A MX2019004402 A MX 2019004402A MX 394475 B MX394475 B MX 394475B
Authority
MX
Mexico
Prior art keywords
methods
inflammatory
inflammation
treatment
related conditions
Prior art date
Application number
MX2019004402A
Other languages
English (en)
Spanish (es)
Other versions
MX2019004402A (es
Inventor
Carlos Batthyány
Carlos Escande
López Germán Galliussi
Gloria López
Duarte Jorge Rodriguez
Marcelo Hill
Nuñes María Garat
Mercedes Segovia
Capuccio Rosina Dapueto
Quinta Williams Porcal
Original Assignee
Inst Pasteur De Montevideo
Carlos Batthyany
Univ La Republica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Pasteur De Montevideo, Carlos Batthyany, Univ La Republica filed Critical Inst Pasteur De Montevideo
Publication of MX2019004402A publication Critical patent/MX2019004402A/es
Publication of MX394475B publication Critical patent/MX394475B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019004402A 2016-10-14 2017-10-16 Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes. MX394475B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408459P 2016-10-14 2016-10-14
US201762570973P 2017-10-11 2017-10-11
PCT/IB2017/056417 WO2018069907A1 (en) 2016-10-14 2017-10-16 Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

Publications (2)

Publication Number Publication Date
MX2019004402A MX2019004402A (es) 2019-09-26
MX394475B true MX394475B (es) 2025-03-24

Family

ID=60382484

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004402A MX394475B (es) 2016-10-14 2017-10-16 Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes.

Country Status (9)

Country Link
US (3) US10537537B2 (enExample)
EP (2) EP3525780B1 (enExample)
JP (1) JP6923659B2 (enExample)
CN (1) CN110325182B (enExample)
AU (1) AU2017342167B2 (enExample)
CL (1) CL2019001014A1 (enExample)
ES (2) ES2886122T3 (enExample)
MX (1) MX394475B (enExample)
WO (1) WO2018069907A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
US11400066B2 (en) * 2016-10-14 2022-08-02 Institut Pasteur De Montevideo Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
EP3525780B1 (en) * 2016-10-14 2021-06-02 Institut Pasteur De Montevideo Pluripotent anti-inflammatory and metabolic modulators for the treatment of inflammation related conditions
BR112020013152B1 (pt) * 2017-12-27 2023-05-09 Institut Pasteur De Montevideo Composto e composição farmacêutica
WO2019145899A1 (en) * 2018-01-24 2019-08-01 Institut Pasteur De Montevideo Methods for treating heart transplant rejection
AU2019344692B2 (en) * 2018-09-20 2025-07-03 Carlos Batthyány Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
US20250367218A1 (en) * 2024-05-14 2025-12-04 Carlos Batthyány Methods of treating metabolic disorders and combination products for use in the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5113140B2 (enExample) * 1972-01-13 1976-04-26
JPS5113140A (en) 1974-07-23 1976-02-02 Sankyo Alu Ind Kinzokuseitoshojino nakazan
ES2136581B1 (es) * 1998-05-27 2000-09-16 Uriach & Cia Sa J Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
WO2005037323A2 (en) * 2003-10-10 2005-04-28 University Of Louisville Research Foundation, Inc. Use of gro to treat or prevent inflammation
US20060247263A1 (en) * 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2012513774A (ja) * 2008-12-31 2012-06-21 ニトロメガ コーポレーション ニトロ脂肪酸を含有する栄養補助物
JP2015521184A (ja) 2012-05-10 2015-07-27 セリックスビオ プライヴェート リミテッド メタボリック症候群の治療のための組成物と治療法
WO2015073527A1 (en) 2013-11-12 2015-05-21 Complexa, Inc. Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
US11400066B2 (en) 2016-10-14 2022-08-02 Institut Pasteur De Montevideo Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
EP3525780B1 (en) 2016-10-14 2021-06-02 Institut Pasteur De Montevideo Pluripotent anti-inflammatory and metabolic modulators for the treatment of inflammation related conditions
WO2019145899A1 (en) * 2018-01-24 2019-08-01 Institut Pasteur De Montevideo Methods for treating heart transplant rejection
AU2019344692B2 (en) 2018-09-20 2025-07-03 Carlos Batthyány Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

Also Published As

Publication number Publication date
US20180104202A1 (en) 2018-04-19
AU2017342167B2 (en) 2023-01-12
EP3878456B1 (en) 2023-03-15
CL2019001014A1 (es) 2019-11-29
CN110325182A (zh) 2019-10-11
MX2019004402A (es) 2019-09-26
US10537537B2 (en) 2020-01-21
EP3525780A1 (en) 2019-08-21
EP3525780B1 (en) 2021-06-02
CN110325182B (zh) 2023-05-23
JP2019531356A (ja) 2019-10-31
US20220296546A1 (en) 2022-09-22
WO2018069907A1 (en) 2018-04-19
AU2017342167A1 (en) 2019-06-06
US12280029B2 (en) 2025-04-22
ES2886122T3 (es) 2021-12-16
JP6923659B2 (ja) 2021-08-25
US20250352501A1 (en) 2025-11-20
ES2945822T3 (es) 2023-07-07
EP3878456A1 (en) 2021-09-15

Similar Documents

Publication Publication Date Title
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
EP3684353A4 (en) TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT
MX385332B (es) Moduladores de ror-gamma.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2019004402A (es) Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.
MX2017005030A (es) Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio.
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX376329B (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX379456B (es) Inhibidores de fde9 con estructura básica de imidazotriazinona y estructura básica de imidazopirazinona en el tratamiento de enfermedades periféricas.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2024013040A (es) Pirfenidona enriquecida con deuterio y metodos para su uso
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
ECSP21031200A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MX2018004295A (es) Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX2019008460A (es) Metodos para tratar esclerosis multiple usando celulas t autologas.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.